Baxter Cardiovascular: Next Stage, Late-Stage
Executive Summary
Baxter is a classic example of a large device company which has lived and grown by the "size is strength" credo; that is, up until recently. Unable to continue growing at an acceptable rate, Baxter adopted the unusual strategy of spinning off major businesses in order to enable both the core company and the new entity to focus on their respective strengths and improve growth. First to go was the hospital supply division, Allegiance Corp., and now Baxter has spun-off its cardiovascular group. To succeed in this crowded market, Baxter Cardiovascular has chosen to focus on an under-developed specialty; late-stage cardiovascular disease.
You may also be interested in...
Edwards: Will a Biotech Deal Strategy Work For a Device Company?
More than two years after being spun-out as Baxter's cardiovascular group, Edwards Lifesciences is establishing its identity as an independent company. A large part of this initial process has focused on which product lines to retain, which to divest, and what new areas to get into. Edwards emerged in the unusual position of having market leadership positions in several product areas, most significantly heart valves. But slow growth in those markets is limiting the extent to which they can drive overall company growth. Edwards' new strategy is to focus on advanced--stage cardiovascular disease with its primary customers being cardiac surgeons. Resource-constrained following the spin-out, the company is relying on a strategy unusual for device companies--alliance, rather than acquisitions--to expand its product offerings. But as the treatment of cardiovascular disease continues to rely increasingly on interventional techniques, the challenge for Edwards is to build a sustainable, broad-based business around selling to cardiac surgeons.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.